Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form

Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors

Academic Article
uri icon
  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Weisberg, E.
  • Liu, Q.
  • Nelson, E.
  • Kung, A. L.
  • Christie, A. L.
  • Bronson, R.
  • Sattler, M.
  • Sanda, T.
  • Zhao, Z.
  • Hur, Wooyoung
  • Mitsiades, C.
  • Smith, R.
  • Daley, J. F.
  • Stone, R.
  • Galinsky, I.
  • Griffin, J. D.
  • Gray, N.

publication date

  • October 2012

journal

  • Leukemia  Journal

subject areas

  • Animals
  • Antineoplastic Combined Chemotherapy Protocols
  • Dasatinib
  • Drug Resistance, Neoplasm
  • Humans
  • Janus Kinases
  • Leukemia, Myeloid, Acute
  • Mice
  • Mutation
  • Protein Kinase Inhibitors
  • Pyrimidines
  • STAT5 Transcription Factor
  • Staurosporine
  • Stromal Cells
  • Thiazoles
  • fms-Like Tyrosine Kinase 3
scroll to property group menus

Research

keywords

  • AC220
  • PKC412
  • acute myeloid leukemia
  • multi-targeted kinase inhibitor
  • stromal-mediated chemoresistance
  • synergy
scroll to property group menus

Identity

PubMed Central ID

  • PMC4054699

International Standard Serial Number (ISSN)

  • 0887-6924

Digital Object Identifier (DOI)

  • 10.1038/leu.2012.96

PubMed ID

  • 22469781
scroll to property group menus

Additional Document Info

start page

  • 2233

end page

  • 2244

volume

  • 26

issue

  • 10

©2021 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support